Pharming Group (NASDAQ:PHAR - Get Free Report)'s share price traded down 3.9% during trading on Tuesday . The stock traded as low as $9.34 and last traded at $10.02. 1,303 shares were traded during mid-day trading, a decline of 75% from the average session volume of 5,267 shares. The stock had previously closed at $10.43.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on PHAR. Oppenheimer cut their target price on Pharming Group from $31.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, October 28th. Jefferies Financial Group assumed coverage on shares of Pharming Group in a research note on Monday, December 9th. They issued a "buy" rating and a $14.00 target price for the company. Finally, HC Wainwright restated a "buy" rating and set a $37.00 price target on shares of Pharming Group in a report on Tuesday, December 17th.
Get Our Latest Research Report on Pharming Group
Pharming Group Stock Performance
The firm has a market cap of $715.66 million, a PE ratio of -40.58 and a beta of 0.05. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The company has a 50-day simple moving average of $8.33 and a two-hundred day simple moving average of $8.15.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its stake in Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,110 shares of the company's stock after acquiring an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 as of its most recent filing with the Securities & Exchange Commission. 0.03% of the stock is currently owned by institutional investors and hedge funds.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
